Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

分组1 - Agios Pharmaceuticals reported a quarterly loss of $1.93 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.74, and compared to a loss of $1.69 per share a year ago, indicating an earnings surprise of -10.92% [1] - The company posted revenues of $12.46 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 34.18%, and showing an increase from $8.61 million in the same quarter last year [2] - Agios Pharmaceuticals shares have increased by approximately 14.2% since the beginning of the year, outperforming the S&P 500's gain of 8.2% [3] 分组2 - The earnings outlook for Agios Pharmaceuticals is uncertain, with current consensus EPS estimates at -$1.87 on revenues of $9.71 million for the upcoming quarter, and -$7.12 on revenues of $40.17 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8] - The estimate revisions trend for Agios Pharmaceuticals was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]